Search research articles
Contact Us
Filters
Showing results (481-490 of 688) with videos related to
Page
of 69
Sort By:
JAMA Cardiology
|
November 13, 2023
Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial
Selim R Krim, Senthil Anand, Stephen J Greene, et al.
Circulation. Heart Failure
|
August 4, 2022
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
Wassim Bedrouni, Abhinav Sharma, Bertram Pitt, et al.
Diabetes Care
|
June 13, 2023
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897
Peter Rossing, Ellen Burgess, Rajiv Agarwal, et al.
International Journal of Cardiology
|
November 6, 2012
The past, present and future of renin-angiotensin aldosterone system inhibition
Robert J Mentz, George L Bakris, Bernard Waeber, et al.
Blood Pressure
|
August 12, 2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study
Sverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Annals of Internal Medicine
|
December 4, 2023
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis
Rajiv Agarwal, Wanzhu Tu, Alfredo E Farjat, et al.
Circulation. Heart Failure
|
December 21, 2018
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction
Senthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
JAMA Cardiology
|
June 14, 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
Rajiv Agarwal, Bertram Pitt, Peter Rossing, et al.
European Journal of Heart Failure
|
April 10, 2026
Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas
Iris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
International Journal of Cardiology
|
February 2, 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
João Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Page
of 69
Search research articles
Search
Showing results (481-490 of 688) with videos related to
Sort By:
Page
of 69
JAMA Cardiology
|
November 13, 2023
Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial
Selim R Krim, Senthil Anand, Stephen J Greene, et al.
Circulation. Heart Failure
|
August 4, 2022
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
Wassim Bedrouni, Abhinav Sharma, Bertram Pitt, et al.
Diabetes Care
|
June 13, 2023
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897
Peter Rossing, Ellen Burgess, Rajiv Agarwal, et al.
International Journal of Cardiology
|
November 6, 2012
The past, present and future of renin-angiotensin aldosterone system inhibition
Robert J Mentz, George L Bakris, Bernard Waeber, et al.
Blood Pressure
|
August 12, 2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study
Sverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Annals of Internal Medicine
|
December 4, 2023
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis
Rajiv Agarwal, Wanzhu Tu, Alfredo E Farjat, et al.
Circulation. Heart Failure
|
December 21, 2018
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction
Senthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
JAMA Cardiology
|
June 14, 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
Rajiv Agarwal, Bertram Pitt, Peter Rossing, et al.
European Journal of Heart Failure
|
April 10, 2026
Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas
Iris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
International Journal of Cardiology
|
February 2, 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
João Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Page
of 69